Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Omniscan

Omniscan

Omniscan is a magnetic resonance imaging (MRI) contrast agent used to enhance visualization of structures and pathologies in the body.
It contains the active ingredient gadodiamide, a gadolinium-based compound that alters the magnetic properties of nearby protons, allowing for improved contrast in MRI scans.
Omniscan is typically administered intravenously and is commonly used to assess the brain, spinal cord, blood vessels, and other organs.
It is particularly useful for detecting and monitoring conditions such as tumors, infections, and inflammation.
Omniscan's safety profile and efficacy in MRI imaging have been well-established through extensive clinical research.
However, as with any medication, it's important to consult with a healthcare provider to determine the appropriate use and potential risks for each individual patient.
Experince the future of Omniscan research today with PubComapre.ai's cutting-edge technology.

Most cited protocols related to «Omniscan»

1
Comprehensive Cardiac MRI Protocol
Cited 10 times
CMR studies were performed using a 1.5 T MR system (Siemens Avanto, Germany). CMR scans assessed LV function, T1-mapping, edema and LGE, with matching short-axis images. T1-mapping was performed using the novel sequence ShMOLLI (Shortened Modified Look-Locker Inversion Recovery) [16 (link)]; dark-blood and bright-blood T2w-CMR were performed with the STIR [8 (link)], and the ACUT2E [10 (link)] sequences, respectively. All were acquired before administration of contrast agents. A 32-channel phased-array chest coil was used for all data acquisition, except for STIR imaging for which the body coil was used. LGE imaging was acquired using a T1-weighted phase-sensitive sequence [18 (link)] 6–10 minutes after intravenous administration of contrast agent (Gadodiamide, Omniscan, GE Healthcare, UK, total 0.13 mmol/kg body weight at 6 ml/s).
Typical imaging parameters for SSFP cine imaging were: voxel size 2.0x2.0x8.0 mm, TR/TE 39.6/1.12 ms, flip angle 55o, matrix 192x192; ShMOLLI T1-maps are based on 5-7 images with specific TI = 100-5000 ms, collected using SSFP readouts in a single breath-hold, typically: TR/TE = 201.32/1.07 ms, flip angle = 35°, matrix = 192x144, 107 phase encoding steps, interpolated voxel size = 0.9x0.9x8mm, cardiac delay time TD = 500 ms; 206 ms acquisition time for single image; STIR [5 (link)]: voxel size 1.9x1.5x10.0 mm, matrix = 256x166, effective echo time TE = 61 ms, effective repetition time TR = 2 RR intervals during breath-hold, flip angle 180o, echo spacing 6.74 ms, TI = 170 ms, dark blood thickness 200 %, dark blood flip angle 180o, turbo factor 25, echo trains per slice = 7; ACUT2E TSE-SSFP: voxel size 1.9x1.5x8.0 mm, matrix = 165x256, TR/TE = 229.70/1.78 ms, effective TE = 98 ms, flip angle 180o, T2 prep duration = 24 ms, segments = 33, 5 shots per slice, bandwidth = 781 Hz/Px); phase-sensitive inversion recovery sequence: voxel size 2.0 x 1.5 x 8.0 mm, matrix 144x256, TR/TE = 800.20/3.36 ms, flip angle 25o).
Ferreira V.M., Piechnik S.K., Dall’Armellina E., Karamitsos T.D., Francis J.M., Choudhury R.P., Friedrich M.G., Robson M.D, & Neubauer S. (2012). Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 14(1), 42.
Full text: Click here
Publication 2012
BLOOD Body Weight Chest Contrast Media ECHO protocol Edema Epistropheus gadodiamide Heart Human Body Intravenous Infusion Inversion, Chromosome Microtubule-Associated Proteins Omniscan Radionuclide Imaging
2
Comparative Myocardial T1 Mapping at 1.5T
Cited 10 times
Matching pairs of ShMOLLI and MOLLI pre-contrast and post-contrast T1 maps were obtained in 4 female subjects (61 ± 3 years old) without pre-existing cardiac disease who underwent a separate research protocol at 1.5T. Subjects underwent adenosine stress perfusion at 140 μg/kg/min for 3 min, followed by a bolus of Gd (Gadodiamide, Omniscan, GE Healthcare, Amersham, UK, 0.03 mmol/kg body weight). After 20 minutes, resting perfusion imaging was performed using 0.03 mmol/kg of Gd followed immediately by a top-up Gd of 0.10 mmol/kg for LGE imaging. Matching T1-maps were obtained at baseline and ~14 minutes after adenosine stress perfusion. Finally, 4 pairs of images were collected before, and one after, the LGE images. The dynamic evolution of T1 recovery after the final Gd bolus was corrected with 3rd order polynomial for the purpose of constructing Bland-Altman plots.
Piechnik S.K., Ferreira V.M., Dall'Armellina E., Cochlin L.E., Greiser A., Neubauer S, & Robson M.D. (2010). Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. Journal of Cardiovascular Magnetic Resonance, 12(1), 69.
Full text: Click here
Publication 2010
Adenosine Biological Evolution Body Weight gadodiamide Heart Microtubule-Associated Proteins Omniscan Perfusion Woman
3
Cardiac MRI Perfusion and Function Assessment
Cited 8 times
All CMR examinations were performed with subjects in a supine position on a 1.5 MR Tesla (Siemens Avanto, Erlangen, Germany) with a 32-element phased-array coil. During the last minute of adenosine infusion a gadolinium-based contrast agent (Gadodiamide, Omniscan®, GE Healthcare or Gadoterate meglumine, Dotarem®, Guerbet S.A.) was administered intravenously at 0.075 mmol/kg body weight (injection rate 4 ml/s), followed by a 20 ml saline flush at the same rate. Perfusion imaging was performed every cardiac cycle during the first pass, using a T1-weighted fast (spoiled) gradient echo sequence (echo time 1.05 ms, repetition time 2 ms, saturation recovery time 100 ms, voxel size 2.3 × 2.8 × 10 mm; flip angle 12°). Three or four short-axis slices, positioned from the base to the apex of the left ventricle, were obtained. The same imaging sequence was repeated at least 10 minutes later without adenosine to obtain perfusion images at rest. For assessment of left ventricular function, steady-state free-precession cine images (TE/TR 1.1/2.6 ms, voxel size 2.0 × 2.0 × 7 mm, flip angle 55°) were acquired in three long-axis views, and a short-axis stack to obtain coverage of the entire left ventricle. Analysis of left ventricular function was performed with Argus Syngo MR software (version B15, Siemens Healthcare, Erlangen, Germany) using the short-axis SSFP images as previously described [7 (link)]. The following left ventricular parameters were thereby determined: end-diastolic volume, end-systolic volume, ejection fraction and myocardial mass.
Karamitsos T.D., Ntusi N.A., Francis J.M., Holloway C.J., Myerson S.G, & Neubauer S. (2010). Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 12(1), 66.
Full text: Click here
Publication 2010
Adenosine Contrast Media Diastole Dotarem ECHO protocol Epistropheus Flushing gadodiamide Gadolinium gadoterate meglumine Heart Left Ventricles Left Ventricular Function Myocardium Omniscan Perfusion Physical Examination Saline Solution Systole
4
Cardiac Magnetic Resonance Perfusion Imaging
Cited 6 times
A standardized CMRI protocol and equipment were used (1.5 T Magnetom Avanto, Siemens Healthcare, Erlangen, Germany). First-pass contrast perfusion imaging was performed using gadolinium contrast of 0.05 mM/kg (Gadodiamide, Omniscan, Amersham, Piscataway, NJ) infused at 4 ml/sec, followed by 20 ml saline at 4 ml/sec. Vasodilator stress was adenosine 140 μg/kg/min infused for two minutes into the arm contralateral to the contrast injection, prior to first-pass perfusion imaging, and continued until completion of the perfusion imaging data acquisition. Resting first-pass perfusion was done 10 minutes later.
Perfusion images were obtained in three left ventricular (LV) short-axis imaging slices (basal, mid and distal LV slice positions) with the following parameters: Gradient echo–EPI hybrid sequence, TR per slice: 148 msec, TE: 1.1 msec, BW: 1420 Hz/pixel, echo train length: 4, readout flip angle: 20°, slice thickness: 8 mm, image matrix: 160 × 70 pixels, in-plane resolution: 2.7 × 2.2 mm2, parallel imaging (GRAPPA) factor: 2, imaging 3 slices every heartbeat. In the event of a peak stress heart rate of >120 bpm, two slices were obtained during stress first-pass imaging with exclusion of the distal LV slice position.
LV function and delayed enhancement imaging were performed using a standardized approach, as previously described13 (link).
Thomson L.E., Wei J., Agarwal M., Haft-Baradaran A., Shufelt C., Mehta P.K., Gill E., Johnson B.D., Kenkre T., Handberg E., Li D., Sharif B., Berman D.S., Petersen J., Pepine C.J, & Bairey Merz C.N. (2015). Cardiac Magnetic Resonance Myocardial Perfusion Reserve Index Is Reduced in Women With Coronary Microvascular Dysfunction: A National Heart, Lung and Blood Institute-Sponsored Study From the Women's Ischemia Syndrome Evaluation (WISE). Circulation. Cardiovascular imaging, 8(4), 10.1161/CIRCIMAGING.114.002481 e002481.
Publication 2015
Adenosine Cardiac Events ECHO protocol Epistropheus gadodiamide Gadolinium Hybrids Left Ventricles Left Ventricular Function Omniscan Perfusion Pulse Rate Saline Solution Vasodilator Agents
5
Multimodal MRI of Traumatic Brain Injury
Cited 6 times
All MRI studies were performed in the UCD Small Animal Imaging Facility. All animals underwent MRI imaging at 72 hours, one week, one month and two months after injury, using pre- and post-gadolinium-enhanced (0.2 mmol/kg Omniscan® IV) T1-weighted, T2-weighted, and diffusion-weighted sequences. For all MRIs, the rats were anesthetized with 2.5% isoflurane. Scans were performed on a 4.7 Tesla Bruker PharmaScan. A quadrature birdcage coil (inner diameter 38 mm, so-called “rat-brain-coil”), tuned to the 1H frequency of 200.27 MHz, was used for RF transmission and reception. T2-weighted MRI (to visualize and confirm injury) was acquired using a rapid acquisition with relaxation enhancement (RARE, Bruker manufacturer label for a fast spin echo sequence) protocol with following parameters: Field of view (FOV) = 4.6 cm; echo time/repetition time (TE/TR) = 100/4,000 msec; slice thickness = 1.20mm; no interslice gaps; number of slices = 18; number of averages = 8; matrix size = 128×256; total acquisition time = 8 min 31 sec. T1-weighted MR images (for volumetric measurements and BBBD assessment) were acquired using a multi-slice multi-echo (MSME, Bruker manufacturer label for a spin echo sequence, in this case with one echo) sequence, before and 5 minutes after administration of 0.2 mmol/kg Omniscan® via tail vein. The following acquisition parameters were used: FOV = 4.6 cm TE/TR = 11/900 msec; slice thickness =1.20 mm with no gaps applied; number of slices = 18; number of averages = 2; matrix size = 128×256; total acquisition time = 3 min 50 sec. Finally, the DWI protocol (for water diffusity/edema assessment) with 6 b-values was acquired using echo-planar imaging with the following parameters: FOV = 4.6 cm; TE/TR = 40/3,000 msec; slice thickness =2 mm with an interslice gap = 0.5 mm between the slices; number of slices = 4; number of averages = 16; b-values = 0, 150, 300, 600, 800 and 1000 sec/mm2 in the x-direction; matrix size = 64×64; total acquisition time = 4 min 48 sec. All images were acquired in the axial orientation.
Frey L., Lepkin A., Schickedanz A., Huber K., Brown M.S, & Serkova N. (2013). ADC mapping and T1-weighted signal changes on post-injury MRI predict seizure susceptibility after experimental traumatic brain injury. Neurological research, 36(1), 26-37.
Publication 2013
Animals Brain Diffusion ECHO protocol Edema Gadolinium Injuries Isoflurane Omniscan Radionuclide Imaging Spin Labels Tail Transmission, Communicable Disease Veins

Most recents protocols related to «Omniscan»

1
Multiparametric MRI Assessment of Focused Ultrasound-Mediated BBB Opening
MRI were acquired to confirm ThUS-mediated BBB opening, track BBB closure, and estimate permeability of the disrupted BBB with Ktrans. To confirm BBB opening, mice were intraperitoneally (IP) administered 0.2 mL of a gadolinium-based MR contrast agent (Omniscan, GE Healthcare, Princeton NJ, USA) and anesthetized with isoflurane throughout the scan in a 9.4T MRI system (Ascend, Bruker Medical, Billerca, MA, USA). T1-weighted 2D FLASH MRI (TR: 230 ms, TE: 3.3 ms, flip angle: 70°, 6 averages, FOV: 25.6 mm x 25.6 mm, matrix size: 256 x 256, slice thickness: 0.4 mm, resolution: 0.1 mm x 0.1 mm, scan time: 5 min) in axial and coronal planes were acquired 30 minutes after BBB disruption for initial confirmation of opening. To track BBB closure, a cohort of mice were administered another bolus injection of contrast agent before acquisition of the same T1-weighted MRI at 7 hours, 24 hours, 48 hours and 72 hours after BBB opening. To estimate closure on a finer timescale of 2 hours post-ThUS, several mice were given the same 0.2 mL bolus injection of contrast agent 1 hour and 30 minutes after ThUS to avoid confounding contrast enhancement signal with accumulation of remaining contrast agent if also previously injected immediately after ThUS. For estimation of permeability constant Ktrans, mice were anesthetized as previously described, catheterized IP, and inserted into the bore of the magnet before dynamic contrast enhanced (DCE) MRI imaging. A modified T1-weighted FLASH sequence (TR: 40 ms, TE: 1.4 ms, flip angle: 50°, 6 averages, FOV: 25.6 mm x 25.6 mm, matrix size: 160 x 160, slice thickness: 0.6 mm, repetitions: 55, scan time: 35 min) was initialized before injection of 0.3 mL contrast agent through the catheter during the 4th repetition. The sequence of resulting images was used to estimate Ktrans.
Batts A.J., Ji R., Noel R.L., Kline-Schoder A.R., Bae S., Kwon N, & Konofagou E.E. (2023). Using a novel rapid alternating steering angles pulse sequence to evaluate the impact of theranostic ultrasound-mediated ultra-short pulse length on blood-brain barrier opening volume and closure, cavitation mapping, drug delivery feasibility, and safety. Theranostics, 13(3), 1180-1197.
Full text: Click here
Publication 2023
Catheters Contrast Media Gadolinium Isoflurane MRI Scans Mus Omniscan Permeability Radionuclide Imaging
2
Gadolinium-Based Contrast Agent Toxicity Study
All methods were carried out in compliance with relevant guidelines and the study was approved by the University of New Mexico’s Institutional Animal Care and Use Committee (IACUC, protocol 21-201088-HSC, Animal Welfare Assurance # D16-00228, A3350-01, USDA Registration # 85-R-0014). Sex-matched wild-type C57/BL6 mice were randomized by weight into untreated (n = 10) or gadolinium-based contrast agent treatment (Omniscan, n = 10) groups13 –18 (link),20 ,21 (link). Male C57/BL6 mice weighed 27 g, whereas female C57/BL6 mice weighed 20 g and were 6–8 weeks of age at the start of the experiment. The contrast agent Omniscan was injected intraperitoneally at a dose of 2.5 mmol per kilogram body weight. This dose is equivalent to twice the clinically approved human dose (human equivalent dose) after adjustment for body surface area and is in accordance with the Food and Drug Administration Guidance for Industry29 . Injections were administered 5 days a week for 4 weeks. The experiments adhered to the ARRIVE guidelines.
DeAguero J., Howard T., Kusewitt D., Brearley A., Ali A.M., Degnan J.H., Jett S., Watt J., Escobar G.P., Dokladny K, & Wagner B. (2023). The onset of rare earth metallosis begins with renal gadolinium-rich nanoparticles from magnetic resonance imaging contrast agent exposure. Scientific Reports, 13, 2025.
Full text: Click here
Publication 2023
Body Surface Area Body Weight Contrast Media Females Gadolinium Homo sapiens Institutional Animal Care and Use Committees Males Mice, House Omniscan
3
Multimodal MRI Evaluation of FUS-Induced BBB Opening
Following the FUS procedure, the mouse was transferred to the Bruker BioSpec 94/20 scanner (field strength, 9.4 T; bore size, 30 cm) horizontal small animal MRI scanner with software ParaVision 6.0.1 (Bruker BioSpin, Billerica, MA, USA), an 86-mm inner diameter birdcage 1H volume transmits coil and a 1H mouse-head-only Cryogenic RF coil (CryoProbeTM). Mice were anesthetized using medical air and isoflurane (3% volume for induction, 1.1–1.5% for maintenance at 1 liter/min airflow, via a nose cone). The DCE-MRI images were acquired using a 2-D FLASH T1-weighted sequence (180 × 150 × 18 × 84 matrix size, spatial resolution of 100 × 100 μm2, slice thickness of 500 μm, TR/TE = 200/2.12 ms) before (i.e., the first four scans) and during the intraperitoneal (IP) injections of the contrast agent Gadodiamide (Gd) (Omniscan; GE Healthcare, Princeton, NJ, USA).
A contrast agent was used as a tracer to depict the area of the BBB-opening. We injected the contrast agent at two time points to obtain MRI scans with different volumes of contrast agent. We first injected 10 mmol/kg GBCAs, which is 3.3% of the full dosage of the GBCAs (low dose), then administered the remaining 97.7% GBCAs (full dose). For each of the injections, we acquired four-dimensional DCE T1-weighted anatomical brain MRI images with 18 slices and 48 acquisitions respectively. The total acquisition time for DCE-MRI was approximately 1 hour. The timeline for FUS and DCE-MRI image acquisition is shown in Fig. 1(a). Schematic showing the timeline for MRI image acquisition and image processing pipeline.
Lee P.Y., Wei H.J., Pouliopoulos A.N., Forsyth B.T., Yang Y., Zhang C., Laine A.F., Konofagou E.E., Wu C.C, & Guo J. (2023). Deep Learning Enables Reduced Gadolinium Dose for Contrast-Enhanced Blood-Brain Barrier Opening. ArXiv.
Publication Preprint 2023
Animals Brain Contrast Media gadodiamide Head Injections, Intraperitoneal Isoflurane Mice, House MRI Scans Nose Omniscan Radionuclide Imaging Retinal Cone TimeLine
4
Gadolinium-Based Contrast Agent Stability Assay
All measurements were
taken on a Bruker Minispec instrument at 60 MHz following a modified
protocol described by Laurent et al.12 (link),13 (link) The following
commercial GBCAs were individually prepared: gadobutrol (Gadovist,
Germany, Bayer), gadoteric acid (Dotarem, France, Guerbet), gadoteridol
(Prohance, Italy, Bracco), gadoxetic acid (Eovist, Germany, Bayer),
gadopentetic acid (Magnevist, Germany, Bayer), gadodiamide (Omniscan,
United States, GE Healthcare), gadofosveset (Ablavar, United States,
Lantheus), and gadobenic acid (Multihance, Italy, Bracco). All solutions
and vessels were warmed to 37.5 °C prior to reaction and measurement.
The experiment was initiated by adding 125 μL of aqueous ZnCl2 to an NMR tube containing 250 μL of phosphate buffer
solution (pH 7.4, divalent metal-free) and 125 μL of the GBCA
being analyzed. The final concentrations of GBCA and ZnCl2 were 2.5 mM, and the final concentration of phosphate buffer was
10 mM. Initial measurements were acquired within 1 min of adding ZnCl2, shaking, and sealing the tube. The same conditions were
replicated for Gd[DTPA-cs124]. Using an inversion recovery sequence,
repetitive T1 measurements were performed
every 6 h at 37.5 °C for each sample for a total of 96 h, and
all GBCAs were measured in triplicate. From the T1 values acquired in the stability assay, R1 values at each time point were calculated, normalized
against the R1 value of each GBCA at 2.5
mM, and plotted as a function of time. The stability ratio was calculated
for each GBCA by taking the ratio of the average measurement at 96
h over the initial measurement at 0 h.
Tranos J.A., Das A., Zhang J., Hafeez S., Arvanitakis G.N., Thomson S.A., Khan S., Pandya N., Kim S.G, & Wadghiri Y.Z. (2023). Rapid In Vitro Quantification of a Sensitized Gadolinium Chelate via Photoinduced Triplet Harvesting. ACS Omega, 8(3), 2907-2914.
Publication 2023
Acids Biological Assay Blood Vessel Buffers Dotarem Eovist gadobenic acid gadobutrol gadodiamide gadofosveset Gadolinium DTPA gadoteridol Gadovist gadoxetic acid Inversion, Chromosome Magnevist Metals MultiHance Omniscan Phosphates Prohance
5
Comprehensive MRI Examination Protocol for Abdominal Imaging
MRI examinations were performed using a 1.5-T MRI scanner (GE Signa HD, GE Healthcare Systems, Milwaukee, WI, USA) with 8- and 12-channel phased-array torso coil. The applied image sequences with scan parameters were shown as follows: repetition time (TR)/echo time (TE) of 520/14 ms, section thickness of 3 mm, field of view (FOV) of 400 × 280 mm2, and matrix of 256 × 256 for the fast-spin-echo-based pre-contrast T1-weighted images with fat suppression; (TR/TE) of 3,500/95 ms, section thickness of 3 mm, FOV of 400 × 280 mm2, and matrix of 320 × 256 for the respiratory-triggered fast-spin echo-based T2-weighted images with fat suppression; TR/TE of 4.9/1.0 ms, section thickness of 3 mm, FOV of 380 × 380 mm2, and matrix of 320 × 288 for the 2D-fast imaging employing steady-state acquisition (2D-FIESTA) in axial and coronal views; TR/TE of 3,600/70 ms, section thickness of 5 mm, FOV of 360 × 360 mm2, and matrix of 128 × 128 for the free-breathing single-shot echo-planar diffusion weighted image with a and b values of 0 and 800 s/mm2, respectively; and TR/TE of 4.1/1.5 ms, section thickness of 3 mm, FOV of 350 × 280 mm2, and matrix of 320 × 256 for the contrast-enhanced T1-weighted images with contrast-enhanced phases including arterial and portal phases. These parameters were applied at 15 s (arterial phase), 60 s (portal phase) after injection of Gadodiamide intravenously (Omniscan, GE; 0.1 mmol/kg body weight) at a rate of 1.5 mL/s by using an autoinjector.
Zhong Y., Zhang H., Wang X., Sun Z., Ge Y., Dou W, & Hu S. (2023). CT and MR imaging features of mixed neuroendocrine–non-neuroendocrine neoplasm of the pancreas compared with pancreatic ductal adenocarcinoma and neuroendocrine tumor. Insights into Imaging, 14, 15.
Full text: Click here
Publication 2023
Arteries Body Weight Diffusion ECHO protocol gadodiamide Microscopy, Phase-Contrast Omniscan Physical Examination Radionuclide Imaging Respiratory Rate Torso

Top products related to «Omniscan»

1
Omniscan by GE Healthcare
Sourced in United States, Ireland, United Kingdom, Germany, China, Norway, France
Omniscan is a contrast agent used in magnetic resonance imaging (MRI) procedures. It is designed to enhance the visibility of certain structures or abnormalities within the body during the imaging process. Omniscan is administered intravenously prior to the MRI scan.
2
Magnevist by Bayer
Sourced in Germany, United States, Japan, China, United Kingdom, Jersey, Canada, Ireland
Magnevist is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI) procedures. It is designed to enhance the visualization of internal body structures and improve the diagnostic capabilities of MRI scans.
3
Magnetom avanto by Siemens
Sourced in Germany, United States, France
The Magnetom Avanto is a magnetic resonance imaging (MRI) system developed by Siemens. It is designed to provide high-quality imaging for a variety of clinical applications. The Magnetom Avanto utilizes a strong magnetic field and radio waves to generate detailed images of the body's internal structures.
4
Omniscan by Daiichi Sankyo
Sourced in Japan
Omniscan is a medical imaging contrast agent manufactured by Daiichi Sankyo. It is used to enhance the visibility of internal structures during medical imaging procedures, such as magnetic resonance imaging (MRI).
5
Gadovist by Bayer
Sourced in Germany, United States, Japan, Canada, Switzerland, United Kingdom, France, Spain
Gadovist is a contrast agent used in magnetic resonance imaging (MRI) procedures. It contains the active ingredient gadobutrol, which enhances the visibility of certain structures within the body during the MRI scan.
6
Dotarem by Guerbet
Sourced in France, Germany, United States, United Kingdom, Italy
Dotarem is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI) procedures. It is designed to enhance the visualization of internal body structures during MRI scans.
7
Signa excite by GE Healthcare
Sourced in United States, United Kingdom, Germany
The Signa Excite is a magnetic resonance imaging (MRI) system developed by GE Healthcare. It is designed to acquire high-quality images of the human body for diagnostic purposes. The system utilizes powerful superconducting magnets and advanced radio frequency (RF) technology to generate detailed images of internal structures, enabling healthcare professionals to identify and monitor various medical conditions.
8
Signa hdxt by GE Healthcare
Sourced in United States, United Kingdom, Germany, Japan, France
The Signa HDxt is a magnetic resonance imaging (MRI) system developed by GE Healthcare. It is designed to provide high-quality, high-resolution medical images for diagnostic purposes. The core function of the Signa HDxt is to generate detailed images of the body's internal structures using strong magnetic fields and radio waves.
9
Discovery 750 by GE Healthcare
Sourced in United States, Germany, China
The Discovery 750 is a high-performance lab equipment product from GE Healthcare. It is designed for advanced imaging and analysis applications in research and clinical settings. The Discovery 750 delivers reliable and consistent results, but a detailed description of its core function is not available while maintaining an unbiased and factual approach.
10
Magnetom skyra by Siemens
Sourced in Germany, United States
The MAGNETOM Skyra is a magnetic resonance imaging (MRI) system developed by Siemens. It is designed to provide high-quality imaging for various medical applications. The MAGNETOM Skyra utilizes advanced technology to generate detailed images of the body's internal structures without the use of ionizing radiation.

More about "Omniscan"

Omniscan is a gadolinium-based magnetic resonance imaging (MRI) contrast agent used to enhance visualization of structures and pathologies in the body.
It contains the active ingredient gadodiamide, which alters the magnetic properties of nearby protons, allowing for improved contrast in MRI scans.
Omniscan is typically administered intravenously and is commonly used to assess the brain, spinal cord, blood vessels, and other organs.
It is particularly useful for detecting and monitoring conditions such as tumors, infections, and inflammation.
Similar gadolinium-based contrast agents like Magnevist, Gadovist, and Dotarem are also widely used in MRI imaging.
These agents, including Omniscan, have been extensively studied and their safety and efficacy in MRI imaging have been well-established.
However, it's important to consult with a healthcare provider to determine the appropriate use and potential risks for each individual patient.
Advances in MRI technology, such as the use of powerful magnets like those found in Magnetom Avanto, Signa Excite, Signa HDxt, and Discovery 750 scanners, have further enhanced the capabilities of gadolinium-based contrast agents like Omniscan.
These cutting-edge MRI systems, combined with the latest imaging techniques, can provide more detailed and accurate visualizations of the body's structures and pathologies.
Experince the future of Omniscan research today with PubCompare.ai's AI-driven platform, which can help researchers and clinicians identify the best protocols and products for their Omniscan studies, improving reproducibility and accuracy.